* Harpoon Therapeutics Inc HARP.OQ HARP.O is expected
to show a rise in quarterly revenue when it reports results on
November 2 (estimated).
* The South San Francisco, California-based company is expected
to report a 61.9% increase in revenue to $6.304 million from
$3.89 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Harpoon Therapeutics
Inc is for a loss of 52 cents per share. For the same quarter
last year, the company reported a loss of 53 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Harpoon
Therapeutics Inc is $30, about 79.1% above its last closing
price of $6.27.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.41 -0.43 -0.52 Missed -19.7
Mar. 31 2021 -0.42 -0.44 -0.37 Beat 16
Dec. 31 2020 -0.48 -0.54 -0.45 Beat 16.7
Sep. 30 2020 -0.47 -0.50 -0.53 Missed -7
Jun. -0.48 -0.47 -0.51 Missed -7.4
30 2020
Mar. 31 2020 -0.36 -0.41 -0.51 Missed -23.5
Dec. 31 2019 -0.48 -0.53 -0.58 Missed -9.5
Sep. 30 2019 -0.55 -0.55 -0.65 Missed -18.1
This summary was machine generated October 29 at 12:07 GMT. All
figures in US dollars unless otherwise stated